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MetabolismAlteration in mitochondrial fusion may regulate mitochondrial metabolism. Since the phospholipid cardiolipin
(CL) is required for function of themitochondrial respiratory chain,we examined the dynamics of CL synthesis in
growing Hela cells immediately after and 12 h post-fusion. Cells were transiently transfected with Mfn-2, to
promote fusion, or Mfn-2 expressing an inactive GTPase for 24 h and de novo CL biosynthesis was examined
immediately after or 12 h post-fusion. Western blot analysis conﬁrmed elevated Mfn-2 expression and electron
microscopic analysis revealed thatHela cellmitochondrial structurewasnormal immediately after and12 hpost-
fusion. Cells expressingMfn-2 exhibited reduced CL de novo biosynthesis from [1,3-3H]glycerol immediately after
fusion and this was due to a decrease in phosphatidylglycerol phosphate synthase (PGPS) activity and its mRNA
expression. In contrast, 12 h post-mitochondrial fusion cells expressing Mfn-2 exhibited increased CL de novo
biosynthesis from [1,3-3H]glycerol and thiswas due to an increase inPGPS activity and itsmRNAexpression. Cells
expressing Mfn-2 with an inactive GTPase activity did not exhibit alterations in CL de novo biosynthesis
immediately after or 12 h post-fusion. The Mfn-2 mediated alterations in CL de novo biosynthesis were not
accompanied by alterations in CL or monolysoCL mass. [1-14C]Oleate incorporation into CL was elevated at 12 h
post-fusion indicating increased CL resynthesis. The reason for the increased CL resynthesis was an increased
mRNA expression of tafazzin, a mitochondrial CL resynthesis enzyme. Ceramide-induced expression of PGPS in
Hela cells or in CHO cells did not alter expression of Mfn-2 indicating that Mfn-2 expression is independent of
altered CL synthesis mediated by elevated PGPS. In addition, Mfn-2 expression was not altered in Hela cells
expressing phospholipid scramblase-3 or a disrupted scramblase indicating that proper CL localization within
mitochondria is not essential for Mfn-2 expression. The results suggest that immediately post-mitochondrial
fusion CL de novobiosynthesis is “sloweddown” and then12 h post-fusion it is “upregulated”. The implications of
this are discussed.y and Therapeutics, Faculty of
e, Winnipeg, Manitoba, Canada
.
atch).
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Cardiolipin (CL) is a major mitochondrial membrane phospholipid
involved inmitochondrial function [reviewed in 1–6]. Reduced CL is one
of the underlying biochemical defects for Barth syndrome, a rare
X-linked genetic disease [reviewed in 7–9]. Mammalian CL is synthe-
sized de novo via the cytidine-5′-diphosphate-1,2-diacylglycerol
(CDP-DG) pathway [10]. In this pathway, phosphatidic acid is converted
to CDP-DG catalyzed by cytidine diphosphate-diacylglycerol synthetase(CDS) [11]. CDP-DG is then condensed with glycerol-3-phosphate to
form phosphatidylglycerolphosphate (PGP) catalyzed by PGP synthase
(PGPS), the committed step of CL de novo biosynthesis. PGP does not
accumulate in mammalian tissues and is rapidly converted to
phosphatidylglycerol (PG) via a highly active PGP phosphatase. In the
ﬁnal step of the pathway, PG is condensed with another molecule of
CDP-DG to form CL catalyzed by CL synthase (CLS) [12]. Several studies
have indicated that CL de novo biosynthesis in mammalian cells may be
controlled at the level of PGPS. For example, during rat liver
regeneration the CL pool is increased via elevated PGPS mRNA
expression and activity [13]. In mutant Chinese hamster ovary (CHO)
cells defective in PGPS at the restrictive temperature, the CL pool is
reduced [14]. In addition, de novo synthesis of mammalian CL may be
controlled by PGPS activity at the level of the transcription factor PPARα
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sphingosine (C2-Cer) stimulated de novo CL synthesis in H9c2 cardiac
myoblasts and in CHO cells via elevated expression of PGPS mRNA and
its activity [17,18]. The Dlc-2 (Stard13) RhoGap gene, when inactivated
by retroviral insertion or RNAi knockdown, prevented C2-Cer induction
of PGPS indicating that Rho signaling normally suppresses induction of
PGPS [18].
Mitochondrial fusion is an active and dynamic process which is
required for growth and maintenance of mitochondria [reviewed in
19–21].The presence of mitofusin (Mfn) is a strict requirement for the
mitochondrial fusion process to occur [22–24]. Mutations in the
mitochondrial GTPase mitofusin-2 (Mfn-2) cause Charcot–Marie–
Tooth neuropathy type 2A, a common yet heterogeneous inherited
neuropathy [25]. Mfn is required to link opposingmitochondrial outer
membranes together via antiparallel dimerization of a coiled-coil
domain [26]. The GTPase domain of Mfn is required for this fusion
process [24,26]. The mechanism through which Mfn interacts with
phospholipids of the outer mitochondrial membrane, such as CL, to
mediate mitochondrial fusion is beginning to emerge. A recent study
indicated that mitochondrial phospholipase D targeted to the external
face of mitochondria promoted transmitochondrial membrane ad-
herence in an Mfn-dependent manner by hydrolyzing CL to generate
PA [27]. CL is localized to both inner and outer mitochondrial
membranes [28,29]. Localization of CL within these membranes is
mediated in part by phospholipid scramblase-3 (PLS3) [30]. Recently,
we showed that altered CL localization mediated by disruption or
elevation of PLS-3 expression stimulated CL de novo biosynthesis [31].
It is likely that maintenance of CL de novo synthesis is important
during and after the mitochondrial fusion process. The dynamics of CL
de novo biosynthesis post-mitochondrial fusion had never been
examined. In this study, we show that immediately post-Mfn-2
mediated mitochondrial fusion in Hela cells CL de novo biosynthesis is
“slowed down” and then 12 h post-fusion it is “upregulated”.
However, CL synthesis or proper localization of CL within the
mitochondria is not a requirement for Mfn-2 expression.
2. Materials and methods
2.1. Materials
Hela cells were obtained from American Type Culture Collection.
[14C]Glycerol-3-phosphate, [5-3H]cytidine 5′-triphophate, [1,3-3H]
glycerol and [1-14C]oleate were obtained from either Dupont,
Mississauga, Ontario, or Amersham, Oakville, Ontario, Canada.
Phosphatidyl[14C]glycerol was synthesized from [14C]glycerol-3-
phosphate as described previously [32]. Dulbecco's modiﬁed Eagle's
medium (DMEM) and fetal bovine serum (FBS) were obtained from
Canadian Life Technologies (GIBCO), Burlington, Ontario, Canada.
Lipid standards were obtained from Serdary Research Laboratories,
Englewood Cliffs, New Jersey, USA. Thin layer chromatographic plates
(silica gel G, 0.25 mm thickness) were obtained from Fisher Scientiﬁc,
Winnipeg, Canada. Ecolite scintillant was obtained from ICN Bio-
chemicals, Montreal, Quebec, Canada. Antibodies to Mfn-2 (Cat. #
M9073) and β-actin (Cat. # 2066) were obtained from Sigma
Chemical Company, St. Louis, MO. USA. ECL Western blotting
detection systemwas from Amersham, Canada. All other biochemicals
were certiﬁed ACS grade and obtained from either Fisher Scientiﬁc,
Winnipeg, Manitoba, Canada or Sigma Chemical Company, St. Louis,
MO. USA.
2.2. Culture, radiolabeling and harvesting of Hela cells
Hela cells were cultured in DMEM supplemented with 10% (v/v)
FBS, and 1% (v/v) penicillin/streptomycin (P/S). Cell cultures were
maintained at 37 °C in humidiﬁed air, containing 5% CO2 until 80%
conﬂuence. Each dish of cells was subcultured at a 1:4 ratio andconﬂuence was usually obtained after 4 days of incubation. Cells were
maintained at a logarithmic growth phase for all experiments. Cells
were transfected with Mfn-2 plasmid or Mfn-2 expressing an inactive
GTPase plasmid (Mfn2RasG12V) for 24 h as previously described [33].
Cells were then incubated for the last 4 hwith DMEM in the absence or
presence of 0.1 mM [1,3-3H]glycerol (10 µCi/dish). In other experi-
ments, cells were transfected with Mfn-2 or Mfn-2 expressing an
inactive GTPase plasmids for 24 h as above and then incubated for 12 h
with 0.1 mM [1,3-3H]glycerol (10 µCi/dish) or 0.1 mM [1-14C]oleate
(2 µCi/dish) bound to albumin in a 1:1 molar ratio. Subsequent to
incubation the medium was removed and the cells washed with 2 ml
of ice-cold phosphate-buffered saline (PBS). The PBSwas removed and
2 ml ofmethanol:water (1:1 v/v)was added. The cells were harvested
using a rubber policeman into test tubes. The mixture was vortexed,
and a 50 µl aliquot was taken for protein determination. 2 ml of
chloroform was added to the tubes followed by 0.5 ml 0.9% NaCl to
initiate phase separation. The tubes were vortexed and then
centrifuged at 2000 rpm for 10 min (bench top centrifuge), the
aqueous phase was removed, and 2 ml theoretical upper phase
(48 ml methanol, 47 ml 0.9% NaCl, and 3 ml chloroform) was added
towash the organic phase. The tubeswere vortexed and centrifuged as
described above and the aqueous phase removed. The organic phase
was dried under a stream of N2 gas and resuspended in 50 µl of
chloroform:methanol (2:1 v/v). A 40 µl aliquot of organic phase was
placed onto a thin-layer plate and phospholipids were separated by
two-dimensional thin-layer chromatography [32]. In some experi-
ments, phospholipid standards were placed onto plates prior to
chromatography and radioactivity incorporated into phospholipids
was determined in the spots corresponding to these phospholipids
[32].2.3. Preparation of subcellular fractions and assay of enzyme activities
All isolation procedures were performed at 4 °C. Subcellular
fractions were prepared from Hela cells transfected with Mfn-2. Cells
were harvested using PBS and pipetted into test tubes. The tubes were
centrifuged at 500×g for 10 min and thePBS removed. Addition of 1 ml
homogenizing buffer (0.25 M sucrose, 10 mM Tris–HCL, 0.145 MNaCl,
pH 7.4)was followed by homogenization by 50 strokes of a tightﬁtting
Dounce A homogenizer. The homogenate was centrifuged at 1000×g
for 10 min and the resulting supernatant centrifuged at 12,000×g for
15 min. The resulting pellet was resuspended in 0.5 ml of homoge-
nizing buffer by a tight ﬁtting Dounce A homogenizer and used as the
source of mitochondrial fraction for assay of mitochondrial enzyme
activities. Mitochondrial phosphatidylglycerolphosphate synthase
(PGPS), cardiolipin synthase (CLS) and monolysocardiolipin acyl-
transferase (MLCL AT) activities were determined as previously
described [32,34].2.4. Quantitative real-time RT-PCR analysis
Ampliﬁcation of each target cDNA was performed with QuantiTect
SYBR Green PCR Master Mix (Qiagen) using a Eppendorff Realplex2
mastercycler according to the protocols provided. The PCR cyclingwas
programmed as 95 °C for 15 s, 55 °C for 30 s and 72 °C for 30 s for
40 cycles. PCR primers used were: human PGP synthase forward,
5′-GAC AAC AACGTC GTC TTG AGT G-3′; reverse, 5′-GAA GTC TGC AAT
CTC AGC ACA G-3′ and for 18s forward, 5′-CTC GGG CCT GCT TTG AAC
AC-3′; reverse, 5′-cgggTGCTCTTAGCTGAGTGTCC[FAM]G-3′. Relative
gene expression was determined using the 2−ΔΔCT method normal-
ized to the 18s levels [35]. Real-time PCR data quality control, 2−ΔΔCT
and analysis of co-variance calculations were run on the SAS program
as described [36]. Primers for human CLS (hCLS1), TAZ, ALCAT1,Mfn-2
and pcr conditions have been described previously [31,37,38].
Fig. 1.Western blot analysis of cells expressing Mfn-2. Hela cells were mock transfected
(lanes 1 and 2) or transfected with Mfn-2 (lanes 3 and 4) or transfected with Mfn-2
with an inactive GTPase (lanes 5 and 6) for 24 h and Western blot analysis was
performed as described inMaterials andmethods. β-actin was used as a protein loading
control. A, Mfn2; B, β-actin. A representative blot is presented.
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Hela cells were transfected with Mfn-2 plasmid for 24 h as above.
The cells were harvested with and homogenized in 10 mM Tris–HCL,
0.25 M sucrose, 2 mM EDTA, 10 mM 2-mecaptoethanol, pH 7.4, by 50
strokes of a tightﬁttingDounce A homogenizer. Mitochondrial fractions
were obtained as above. Aliquots containing 25 µg of mitochondrial
fraction protein were separated by SDS-polyacrilamide gel electropho-
resis (SDS-PAGE) on a 7.5% acrylamide gel with molecular weight
standards, using a BioRad Mini-Protean® II Dual Slab Cell electropho-
resis unit. Protein from the separating gel was blotted onto PVDF
membranes for 90 min at 15 V using a BioRad Trans-Blot SD Semi-Dry
Transfer Cell. The expression of Mfn-2 was examined by immunoblot-
ting in 10 ml Tris-buffered saline containing 0.1% Tween-20 with anti-
Mfn-2 antibody (1:250 dilution) or (40 µl antibody dissolved in 10 ml
Tris-buffered saline containing 0.1% Tween-20) at 4C overnight.
Subsequently, the membrane was washed and incubated with
peroxidase labeledanti-rabbit IgG secondary antibody(1:1000dilution)
for 1 h at room temperature. Expression of β-actin was examined by
incubating the PVDF membrane with anti-β-actin antibody under the
conditions described [39]. Identiﬁcation was according to ECL Western
blotting analysis system. Protein bands in the membrane were
visualized by enhanced chemiluminescence.
2.6. HPLC-MS analysis of CL and MLCL
HPLC-MS analysis of CL and MLCL was performed as previously
described [40]. The HPLC system consisted of a Surveyor quaternary
gradient pump, a vacuum degasser, a column temperature controller,
and anautosampler (ThermoElectron,Waltham,MA, USA). The column
temperature was maintained at 25 °C. The lipid extract was injected
onto a LiChrospher 2×250-mm silica-60 column, 5 μm particle
diameter (Merck, Darmstadt, Germany). The phospholipids were
separated from interfering compounds by a linear gradient between
solution B (chloroform/methanol, 97:3, v/v) and solution A (methanol/
water, 85:15, v/v). SolutionsAandB contained1and0.1 mlof 25% (v/v)
aqueous ammonia per liter of eluent, respectively. The gradient (0.3 ml/
min) was as follows: 0–10 min, 20% A–100% A; 10–12 min, 100% A;
12–12.1 min, 100% A–0% A; and 12.1–17 min, equilibration with 0% A.
All gradient steps were linear, and the total analysis time, including the
equilibration, was 17 min. A splitter between the HPLC column and the
mass spectrometerwas used, and 75 μl/min eluentwas introduced into
the mass spectrometer. A TSQ Quantum AM (Thermo Electron) was
used in the negative electrospray ionizationmode. Nitrogenwas used as
the nebulizing gas. The source collision-induced dissociation collision
energy was set at 10 V. The spray voltage used was 3600 V, and the
capillary temperature was 300 °C. Mass spectra of CL and MLCL
molecular species were obtained by continuous scanning from m/z
380 tom/z 1100 with a scan time of 2 s. CL(14:0)4 was used as internal
standard.
2.7. Other determinations
Protein was determined by the method of Lowry using bovine
serum albumin as the standard [41]. Electronmicrographs of Hela cells
were prepared as previously described [42]. Student's t-test was used
for determination of statistical signiﬁcance. The level of signiﬁcance
was deﬁned as pb0.05.
3. Results
Mfn-2 is a key protein involved in mediating mitochondrial fusion
but the dynamics of CL de novo biosynthesis post-fusion had never
been examined. It was previously shown that cells overexpressing
Mfn-2 have increased rates of fusion [33]. Following 12–24 h of
expression, the mitochondria were seen to clump into a completelyfused reticulum, indicating that mitochondrial ﬁssion cannot proceed
in these cells. Electron microscopy showed that these organelle
clusters were connected through an extensive array of fused outer
membranes, consistent with uncontrolled fusion between adjacent
organelles. In contrast, cells expressing Mfn-2 for 24 h were also
clustered, however electron microscopy and fusion assays did not
reveal any fusion between the membranes. Therefore we used longer
time points when all of the mitochondria appear irreversibly fused as
relevant time points for lipid analysis.
To determine if CL de novo biosynthesis was regulated post-
mitochondrial fusion, Hela cells were transiently transfected with
Mfn-2 or Mfn-2 with an inactive GTPase for 24 h to promote
mitochondrial fusion and expression of Mfn-2 mRNA examined.
Real-time PCR analysis indicated that transfectionwithMfn-2 resulted
in elevated mRNA expression of Mfn-2 and Mfn-2 with an inactive
GTPase (data not shown). Western blot analysis conﬁrmed that Mfn-2
protein expression was elevated in Hela cells transfected with either
Mfn-2 or Mfn-2 with an inactive GTPase compared to vector controls
(Fig. 1). Since cells were incubated with the plasmid for 24 h
mitochondrial fusion should be complete. We performed electron
microscopy studies to examine the structure of themitochondria post-
fusion. In cells expressing Mfn-2, mitochondrial size and morphology
was indeed comparable to control Hela cells immediately after fusion
and at 12 h post-fusion (Fig. 2A, B, C).
To determine if CL biosynthesis was altered immediately post-
fusion, Hela cells were transiently transfected with Mfn-2 for 24 h and
with [1,3-3H]glycerol for the last 4 h and radioactivity incorporated into
CL examined. Incorporation of [1,3-3H]glycerol into CLwas reduced 55%
(pb0.01) inMfn-2 expressing cells compared tomock control (Fig. 3A).
Incorporation of [1,3-3H]glycerol into all other phospholipids examined
was unaltered (Fig. 3B). Total uptake of [1,3-3H]glycerol into control
cells was 3.4±0.3×105 dpm/mg protein and was unaltered in Mfn-2
expressing cells (3.9±0.3×105 dpm/mg). Thus, the reduction in [1,3-
3H]glycerol incorporated into CLwas not due to changes in total uptake
of [1,3-3H]glycerol. Incorporation of [1,3-3H]glycerol into CL and other
phospholipids was unaltered in Mfn-2 expressing an inactive GTPase
compared tomock control (Fig. 3C, D). These data indicate that an active
GTPase component of Mfn-2 was essential for attenuation of CL
biosynthesis from [1,3-3H]glycerol in Hela cells.
The reason for the reduction in incorporation of [1,3-3H]glycerol
into CL in Mfn-2 expressing cells was examined. Hela cells were
transiently transfected with Mfn-2 for 24 h and PGPS and CLS enzyme
activities determined. CLS activity was unaltered in Mfn-2 expressing
cells (Table 1). In contrast, PGPS activity was reduced 30% (pb0.01) in
Mfn-2 expressing cells compared to mock transfected controls. The
reduction in PGPS activity was due to a corresponding reduction in the
mRNA expression of PGPS (Fig. 4A). CLS mRNA expression was
unaltered (data not shown). Thus, the decrease in [1,3-3H]glycerol
incorporation into CL was due to a reduced activity and expression of
Fig. 2. EM analysis of cells expressing Mfn-2. Hela cells were mock transfected (A) or
transfected with Mfn-2 for 24 h (B) or transfected with Mfn-2 for 24 h followed by
incubation for a further 12 h (C) and EM analysis was performed as described in
Materials and methods. Representative micrographs are presented. Bar is equivalent to
1 micrometer (1 μm).
Fig. 3. CL de novo biosynthesis from [1,3-3H]glycerol in cells expressing Mfn-2 or Mfn-2
expressing an inactive GTPase incubated for 4 h. Hela cells were mock transfected or
transfected for 24 h with Mfn-2 (A, B) or Mfn-2 expressing an inactive GTPase (C, D) and
were incubated for the last 4 hwith [1,3-3H]glycerol and radioactivity incorporated intoCL
(A, C), and other phospholipids (B, D) were determined as described in Materials and
methods. Closed bars, mock transfected cells; open bars, cells expressing Mfn-2 or Mfn-2
with an inactive GTPase. PG, phosphatidylglycerol; PS/PI, phosphatidylserine/phospha-
tidylinositol; PE, phosphatidylethanolamine; PC, phosphatidylcholine. Data represent the
mean±standard deviation of at least three experiments. *pb0.05.
Table 1
Enzyme activities in cells expressing Mfn-2. Hela cells were transfected with Mfn-2 and
mitochondrial fractions prepared immediately or 12 h post-transfection and PGPS, CLS
and PLA2 activities were determined as described in Materials and methods. Data
represent the mean±standard deviation of three experiments. N.D., not determined.




PGPS 197±8 141±6⁎ 273±21⁎
CLS 3.1±0.3 3.3±0.3 2.9±3
PLA2 5.3±0.8 N.D. 5.5±0.1
⁎ pb0.05.
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de novo biosynthesis immediately post-fusion.
We next examined if the reduced CL de novo biosynthesis
immediately post-fusion was associated with reduced levels of CL or
its principal metabolite MLCL. Hela cells were transiently transfected
with Mfn-2 for 24 h and phospholipid content examined using mass
spectrometry analysis. The content of CL and MLCL were unaltered in
Mfn-2 expressing cells (Fig. 5A–C).
Todetermine if CL biosynthesiswas altered12 h after fusion,Hela cells
were transiently transfected with Mfn-2 for 24 h then incubated with
[1,3-3H]glycerol for 12 h and radioactivity incorporated into CL examined.
Surprisingly, [1,3-3H]glycerol incorporated into CL was increased 3-fold
(pb0.03) (Fig. 6A) and into PG 2-fold (pb0.02) (Fig. 6B) in Mfn-2
expressing cells compared to control at 12 h post-transfection. Incorpo-
ration of [1,3-3H]glycerol into PC, PE and PS/PI was increased 60%
(pb0.01), 31% (pb0.03) and45%(pb0.04) (Fig. 6C). Total [1,3-3H]glycerol
incorporated into control cells was 7.8±0.2×105 dpm/mg protein and
was unaltered in Mfn-2 expressing cells (8.0±0.4×105 dpm/mg). Thus,the elevation in radioactivity incorporated intophospholipidswasnot due
to changes in total uptake of [1,3-3H]glycerol. In Hela cells expressing
Mfn-2with an inactive GTPase therewas no alteration in [1,3-3H]glycerol
incorporated into all phospholipids at 12 h post-transfection (data not
Fig. 4. Expression of PGPS mRNA in cells expressing MFN-2. Hela cells were transfected
with Mfn-2 and total RNA isolated and expression of PGPS mRNA was determined
immediately after or 12 h post-fusion as described in Materials and methods. A.
Immediately after fusion. B. 12 h post-fusion. C. Mock transfected Hela cells; Mfn-2,
Hela cells transfected with Mfn-2. Results represent ratio of PGPS to 18s ribosomal RNA.
Data represent the mean±standard deviation of three experiments. *pb0.05.
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component of Mfn-2 is essential for modulation of CL biosynthesis from
[1,3-3H]glycerol in Hela cells.
The reason for the increased incorporation of [1,3-3H]glycerol into
CL was examined. Hela cells were transiently transfected with Mfn-2
for 24 h and PGPS and CLS enzyme activities determined 12 h post-
fusion. CLS activity was unaltered in Mfn-2 expressing cells (Table 1).
In contrast, PGPS activity was increased 39% (pb0.01) in Mfn-2
expressing cells compared to control. The increase in PGPS activitywas
due to a corresponding increase in the mRNA expression of PGPS
(Fig. 4B). In contrast, CLS mRNA expression was unaltered (data not
shown). Thus, the increase in [1,3-3H]glycerol incorporation into CL
12 h post-mitochondrial fusion was due to an increased activity and
mRNAexpression of PGPS. Together these data indicate that CL de novo
biosynthesis was reduced immediately after mitochondrial fusion
process but is upregulated 12 h post-fusion.
Unsaturated fatty acids enter into CL mainly by remodeling
processes [reviewed in 3,7]. The major unsaturated fatty acid found in
Hela cells phospholipids is oleate (18:1) comprising almost 50% of the
total [44]. We examined if the observed alterations in CL de novo
biosynthesis were associated with alteration in [1-14C]oleate incorpo-
rated into CL. Hela cells were transfected with Mfn-2 for 24 h and then
incubated with [1-14C]oleate and radioactivity incorporated into CL
determined immediately after or 12 h post-transfection. Incorporation
of [1-14C]oleate into all phospholipids were unaltered in Mfn-2
expressing cells compared to control immediately post-fusion (data
not shown). In addition, total [1-14C]oleate incorporated into cells was
2.5×105 dpm/mg protein and was unaltered in Mfn-2 expressing cells
(2.5×105 dpm/mg). In contrast, incorporation of [1-14C]oleate into CL
was increased 66% (pb0.007) in Mfn-2 expressing cells compared to
control at 12 h post-fusion (Fig. 7A). [1-14C]Oleate incorporated into PG
(Fig. 7B) and other phospholipids (Fig. 7C) was unaltered. Total [1-14C]
oleate incorporated into cells was 8.6×105 dpm/mg protein and was
unaltered in Mfn-2 expressing cells (8.2×105 dpm/mg). Thus, the
elevation in radioactivity incorporated into CLwasnot due to changes in
total uptake of [1-14C]oleate in the transfected cells. In Hela cells
expressing Mfn-2 with an inactive GTPase there was no alteration in
[1-14C]oleate incorporated into phospholipids immediately after or 12 h
post-fusion (data not shown). Thus, the increase in [1-14C]oleateincorporation into CL by accompanied the elevation in CL de novo
biosynthesis 12 h post-mitochondrial fusion.
The reason for the increase in [1-14C]oleate incorporation into CL in
MFN-2 expressing cells 12 h post-fusion was examined. Hela cells were
transfected with Mfn-2 for 24 h and then mitochondrial PLA2 and
expression/activity of the CL remodeling enzymes TAZ/MLCL AT and
expression of the endoplasmic reticulum CL resynthesis enzyme
ALCAT1 were examined 12 h post-transfection. Expression of TAZ
mRNA was increased 30% (pb0.05) 12 h post-fusion (Fig. 8A). In
contrast, expression of ALCAT1mRNAwas unaltered (Fig. 8B). MLCL AT
activity was unaltered (data not shown). In addition, PLA2 activity was
unaltered in cells transfectedwithMfn-2 (Table 1). Thus the increase in
CL resynthesis from [1-14C]oleate in Mfn-2 expressing cells 12 h post-
fusion was likely due to an increase in expression of the mitochondrial
CL resynthesis enzyme TAZ.
We previously demonstrated that N-acetylsphingosine (C2-Cer)
induced PGPS activity and its mRNA expression in H9c2 cardiac
myoblast cells and in CHO cells and this lead to elevation in de novo
CL biosynthesis but that C2-Cer did not alter PGPS activity or CL
biosynthesis in Stard13 mutant CHO E91 cells resistant to C2-Cer
induced apoptosis [17,18]. We tested the hypothesis that forced PGPS
expressionandelevationofCL synthesis itselfwoulddirectly alterMfn-2
mRNA expression. Hela cells were incubated in the absence or presence
of 30 µM C2-Cer for 24 h and the mRNA expression of Mfn-2
determined. PGPS enzyme activity was 197±8 pmol/min/mg protein
inHela cells andwas elevated35% (*pb0.05) to265±12 pmol/min/mg
protein in Hela cells treated with C2-Cer. Mfn-2 mRNA expression was
unaltered in cells incubated in the absence or presence of C2-Cer
(Fig. 9A). CHO K1 cells or C2-Cer resistant CHO E91 cells were then
incubated in the absence or presence of 30 µM C2-Cer for 24 h and the
mRNA expression of Mfn-2 determined. PGPS enzyme activity was
elevated 35–39% in CHO K1 cells but not in CHO E91 cells as previously
described [18]. Interestingly, Mfn-2mRNA expression was reduced 50%
in both CHO K1 and in CHO E91 cells resistant to C2-Cer induced
apoptosiswhen these cells were incubatedwith C2-Cerwhen compared
to controls (Fig. 9B). These data indicate that forced expression of PGPS
mRNAandactivity andhence elevatedCLbiosynthesis doesnot alter nor
is linked to the expression ofMfn-2. However, C2-Cer incubation of CHO
cells inhibited Mfn-2 mRNA expression independent of PGPS expres-
sion. The data indicate that elevation in CL synthesis doesnot affectMfn-
2 expression.
Phospholipid scramblase-3 (PLS3) is a unique member of the
phospholipid transfer protein family and transports CL between inner
and outer mitochondrial membranes [30]. We previously showed that
CL de novo biosynthesis was elevated in Hela cells expressing PLS3
(PLS3) or Hela cells expressing a disrupted PLS3 (F(258)V) [31]. To
further examine if elevation in CL synthesis was not directly linked to
Mfn-2 expression, we examined if alteration of CL localization within
the mitochondria would affect expression of Mfn-2. Mfn-2 mRNA
expression was examined in vector, PLS3 or F(258)V Hela cells. Mfn-2
mRNA expression was unaltered between control, PLS3 or F(258)V
cells (data not shown). These data further conﬁrm that elevation in CL
synthesis is not directly linked to mitochondrial fusion and proper CL
localization within mitochondria is not essential for Mfn-2 mRNA
expression.
4. Discussion
In this study we examined the dynamics of CL de novo biosynthesis
immediately after and 12 h post-mitochondrial fusion. The major
ﬁndings of this paper are 1. CL de novo biosynthesis is reduced
immediately post-Mfn-2-mediated mitochondrial fusion and this is
due to a reduction in the activity and mRNA expression of PGPS, 2. 12 h
post-Mfn-2 induced mitochondrial fusion, CL de novo biosynthesis is
upregulated and this is mediated by an increase in activity and mRNA
expression of PGPS, 3. the upregulation in CL de novo biosynthesis is
Fig. 5. CL and MLCL content in Hela cells expressing Mfn-2. Hela cells were mock transfected (1, 3) or transfected with Mfn-2 (2, 4) and CL (A) and MLCL (B) were determined by
mass spectrometry analysis as described in Materials and methods. C. A representative spectra of CL and MLCL analysis. Data represent the mean±standard deviation of three
experiments.
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mitochondrial fusion, 4. expression or knock down of PGPS mRNA and
enzyme activity does not itself alter expression of Mfn-2, 5. proper
localization of CL is not required for expression of Mfn-2, and 6.
mitochondrial fusion regulates CL synthesis. The results of the current
study provide evidence that CL de novo biosynthesis is “slowed down”
immediately post-mitochondrial fusion but is then “upregulated” 12 h
post-fusion.
Hela cells expressing a functionalMfn-2 exhibited reduced CL de novo
biosynthesis from [1,3-3H]glycerol and thiswas due to adecrease in PGPS
activity andmRNA expression during fusion. Expression ofMfn-2 did not
alter the biosynthesis of other phospholipids from [1,3-3H]glycerol
indicating that the effect of Mfn-2 expression was speciﬁc to mitochon-
drial CL. InHela cells expressingMfn-2withan inactiveGTPaseCLdenovo
biosynthesis was unaltered indicating that the GTPase component of
Mfn-2 is critical for regulation of CL biosynthesis by Mfn-2. The results
suggest thatmitochondrial CL de novo biosynthesis is apparently “slowed
down” immediately post-fusion. Interestingly, radioactivity incorporated
into PGwas unaltered even though PGPS activity was decreased in these
cells. This is likely due to the rapidmovement of [1,3-3H]glycerol fromPGto CL in mammalian cells [10]. In contrast, 12 h post-fusion PG and CL de
novo biosynthesis from [1,3-3H]glycerol were elevated and this was due
to a increase in PGPS activity and its mRNA expression indicating that
once fusion is completed CL de novo biosynthesis is upregulated. The
increase in [1,3-3H]glycerol incorporation into the other phospholipids at
12 hpost-fusion is likely required to support the increasedmitochondrial
biogenesis although the level of elevated synthesiswas lower than that of
mitochondrial CL.
The PGPS and CLS enzymes have little fatty acyl substrate speciﬁcity
for precursors of CL [3]. Thus, de novo synthesized CL must be rapidly
remodeled to obtain the speciﬁc fatty acyl molecular composition of CL
seen in themitochondria.Hela cell CL is highly enrichedwitholeate [43].
Cells expressing functional Mfn-2 exhibited increased [1-14C]oleate
incorporation into CL at 12 h but this was unaltered during fusion.
Although a portion of [1-14C]oleate incorporation into CL may have
come from increased primary biosynthesis, the increased [1-14C]oleate
incorporation into CL 12 h post-fusion in Hela cells expressing Mfn-2
was accompanied by an increased expression of the mitochondrial CL
resynthesis enzyme TAZ. In contrast, [1-14C]oleate incorporation into CL
was unaltered during and 12 h post-fusion in Hela cells expressing
Fig. 6. CL de novo biosynthesis from [1,3-3H]glycerol in cells expressing Mfn-2
incubated for 12 h. Hela cells were mock transfected or transfected with Mfn-2 and
then incubated for 12 h with [1,3-3H]glycerol and radioactivity incorporated into CL
(A), PG (B) and other phospholipids (C) was determined as described in Materials and
methods. Closed bars, mock transfected cells; open bars, cells expressing Mfn-2. Data
represent the mean±standard deviation of three experiments. *pb0.05.
Fig. 7. CL synthesis from [1-14C]oleate in cells expressing MFN-2. Hela cells were
transfected with Mfn-2 for 24 h and then incubated for 12 h with [1-14C]oleate and
radioactivity incorporated into CL (A), PG (B) and PS/PI, PE and PC (C) was determined
as described in Materials and methods. A. Data represent the mean±standard
deviation of three experiments. *pb0.05.
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was required for [1-14C]oleate incorporation into CL 12 h post-fusion.
Since CL de novo biosynthesis was slowed down during fusion it would
not be expected that [1-14C]oleate entrance into CL via remodeling
would be altered inMfn-2 expressing cells. In contrast, an increase in [1-
14C]oleate incorporation into CL might be expected to accompany the
elevation in de novo CL biosynthesis seen 12 h post-fusion in Mfn-2
expressing cells.
Does altered PGPS expression and CL de novo biosynthesis itself
regulate Mfn-2 expression? We tested this directly by examining
Mfn-2 mRNA expression in C2-Cer-treated Hela cells which exhibited
elevated PGPS activity. Since elevation of PGPS activity mediated by
C2-Cer did not affect Mfn-2 mRNA expression in Hela cells, it can be
concluded that elevated PGPS activity and hence CL biosynthesis itself
does not control Mfn-2 expression in Hela cells. In Hela cells, C2-Cer
was previously shown to stimulate mitochondrial network fragmen-
tation linked to endoplasmic reticulum calcium release and cell death
[44]. A more recent study in isolated cardiac myocytes showed that
downregulation of Mfn-2 levels to 75% of control, mediated by RNA
knock down, resulted in increased mitochondrial ﬁssion in isolated
cardiac myocytes [45]. However, this did not enhance C2-Cer induced
mitochondrial fragmentation. In the current study, C2-Cer addition to
both CHOK1 and CHOE91 cells resistant to C2-Cer-mediated apoptosis
exhibited decreased Mfn-2 mRNA expression. Since E91 cells show
resistance to C2-Cer induced apoptosis [18], it is likely that the effects
of C2-Cer onmitochondrial-mediated apoptosis are not directly linked
to mitochondrial fusion. Taken together, the results of these studies
and our current study support the notion that the C2-Cer-mediated
fragmentation of mitochondria may not involve Mfn-2 directly.Does altered CL localization affect Mfn-2 expression?We tested this
directlybyexaminingmitochondrial fusion inHela cells expressingPLS3
(PLS3) or an inactive PLS3 (F258V). PLS3 expression was shown to
increase CL localization on the outer mitochondrial membranewhereas
expression of inactive PLS3 resulted in CL accumulation on the inner
mitochondrial membrane [30]. Expression of Mfn-2 in PLS3 cells and in
F258V cells expressing an inactive PLS3 was unaltered compared to
control Hela cells indicating that expression of Mfn-2 is independent of
mitochondrial localization of CL. We previously showed that CL
biosynthesis was elevated in PLS3 Hela cells expressing PLS3 or Hela F
(258)V cells expressing a disrupted PLS3 [31]. That study and our
current study suggest that the mitochondrial fusion process may be
regulated independently of CL de novo biosynthesis.
Why is CL synthesis altered post-mitochondrial fusion? It is possible
that during mitochondrial fusion CL biosynthesis is “slowed down” in
order to allow for uninterrupted fusion of individual mitochondria to
occur. Thismay be related to the energy price of disruption and bending
ofmembrane lipid bilayers duringbilayer fusion [46,47]. Alternatively, it
Fig. 8. Expression of TAZ and ALCAT1 mRNA in cells expressing MFN-2. Hela cells were
transfected with Mfn-2 and total RNA isolated 12 h post-fusion and mRNA expression
of TAZ (A) and ALCAT1 (B) was determined as described inMaterials andmethods. Data
represent the mean±standard deviation of three experiments. *pb0.05.
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mitochondrial biogenesis. We recently showed that loss of CL on the
outer mitochondrial membrane by disruption of PLS3 resulted in
elevated CL biosynthesis in Hela cells likely in an attempt to restore CL
on the outer surface of the outer mitochondrial membrane [31]. It is
possible that CL de novo biosynthesis is upregulated 12 h post-fusion in
order to replace CL lost from the outermitochondrial membrane during
Mfn-mediatedphospholipaseDhydrolysis of CLon theoutermembrane
[27]. However, MS analysis of cells immediately post-fusion did not
reveal any change in the level CL nor itsmetaboliteMLCL indicating that
it is not a change in the CL or MLCL pool size per se that results in the
stimulation of CL biosynthesis. In addition, the PA levels were low andFig. 9.Mfn-2 expression inHela cells and inCHOK1andCHOE91 cells treatedwith C2-Cer.
A. Hela cells were incubated in the absence (closed bar) or presence (open bar) of 30 µM
C2-Cer for 24 h and mRNA expression of Mfn-2 was determined as described in Materials
and methods. B. CHO K1 (1, 2) or E91 (3, 4) cells were incubated in the absence (1, 3) or
presence (2, 4) of 30 µMC2-Cer for 24 h andmRNAexpressionofMfn-2wasdetermined as
described inMaterials andmethods. Results represent ratio ofMfn-2 to18s ribosomal RNA.
Data represent the mean±standard deviation of three experiments. *pb0.05.were unaltered in Mfn-2 treated cells (data not shown). Moreover, EM
analysis indicated that Hela cell mitochondria appeared morphologi-
cally normal immediately after and 12 h post-fusion. Finally, new
synthesis of all phospholipids from [1,3-3H]glycerol or [1-14C]oleatewas
elevated 12 h post-fusion. We suggest that the upregulation of CL
biosynthesis observed 12 h post-fusion in Hela cells may be required to
restore the normal rates of CL biosynthesis. In addition, it appears that
mitochondrial fusion may regulate cellular phospholipid biosynthesis
from [1,3-3H]glycerol and [1-14C]oleate precursors.
The data presented here have shown that active Mfn-2 signals for
increased mitochondrial biogenesis, leading to the upregulation of
lipid synthesis pathways. This is consistent with the emerging
evidence that Mfn-2, unlike Mfn-1, appears to have signaling
capabilities that link the health of the mitochondria with their
biogenesis. We believe that this is an important new ﬁnding that
provides compelling new evidence to implicate the fusion machinery
with the control of mitochondrial numbers. Future work will uncover
the signaling intermediates that linkMfn-2 to the upregulation of lipid
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